Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-blind, Placebo Controlled, Double Dummy, Single-centre Trial in Healthy Subjects Comparing the Steady-state Exposure of Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly

NCT02557620 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT02557620
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02557620 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-blind, Placebo Controlled, Double Dummy, Single-centre Trial in Healthy Subjects Comparing the Steady-state Exposure of Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2015
Completion date
April 30, 2016
Enrollment
113 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, healthy